Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT03922776

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer — TILsOV-1805  

Ovarian Cancer Stage IV Clinical Trial

Official title:
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy

Clinical Trial Summary

This is a monocenter, interventional, non-randomized study among women patients with an ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a neo-adjuvant chemotherapy then surgery +/- adjuvant chemotherapy. The planned interventions are collection of biological samples at different times. The study will aim to describe the immunological profile at diagnosis in terms of phenotypic : PBMCs (peripheral blood, mononuclear cells) in peripheral blood, TILs (tumor-infiltrating lymphocytes) in ascites and in carcinomatosis.

Clinical Trial Description

Participants will receive the following interventions because they are enrolled in the study: blood sample collection - at diagnosis, before chemotherapy (pre-CT) - after chemotherapy (post-ct) Two additional blood samples will be collected in each patient : one at diagnosis and one at the end of chemotherapy. The aim of this study is to describe the immunological profile at diagnosis in terms of phenotypic : PBMC in peripheral blood, TILs in ascites and in carcinomatosis, in patients treated for peritoneal carcinomatosis of ovarian or tubal origin. The treatment has to be a surgery and an adjuvant chemotherapy, or a neo-adjuvant chemotherapy followed by a surgery +/- adjuvant chemotherapy. Other objectives of the study include: - Evaluate the association between the immunological profile at diagnosis and the characteristics of the disease at diagnosis (histological type, extension) - Evaluate the prognostic value of the immunological profile at diagnosis in terms of clinical response to neoadjuvant chemotherapy (for patients with interval surgery) - Evaluate the polarization of the immune response induced by chemotherapy, describing the phenotypic changes in the different types of samples (blood, +/- ascites, +/- carcinomatosis) after chemotherapy in comparison with samples at diagnostic - Evaluate the association between these immunological phenotypic changes and the clinical response to chemotherapy in patients receiving neoadjuvant chemotherapy - Collect biological material for peritoneal carcinomatosis for subsequent biological analyzes ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03922776
Study type Interventional
Source Centre Oscar Lambret
Contact Marie Vanseymortier
Phone 03 20 29 59 18
Email promotion@o-lambret.fr
Status Recruiting
Phase N/A
Start date May 16, 2019
Completion date May 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT00945191 - Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer Phase 2
Recruiting NCT03579394 - Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT04701645 - Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Phase 1
Recruiting NCT03126812 - Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer Phase 1/Phase 2
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Completed NCT03085238 - Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer N/A
Recruiting NCT04938583 - Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06017557 - Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) N/A
Suspended NCT05479045 - A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients Phase 2
Completed NCT05005650 - Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
Recruiting NCT03899610 - A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) Phase 2
Recruiting NCT04789694 - Prehabilitation in Gynaecological Cancer Patients Phase 3
Not yet recruiting NCT05187208 - PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Phase 4
Recruiting NCT06272240 - Tumor Microenvironment in Ovarian Cancer
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Active, not recruiting NCT03275506 - PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . Phase 2
Recruiting NCT06290193 - Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery Phase 2
Completed NCT02258165 - Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Recruiting NCT03693248 - Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Phase 3